Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

101 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial.
Frenel JS, Kim JW, Aryal N, Asher R, Berton D, Vidal L, Pautier P, Ledermann JA, Penson RT, Oza AM, Korach J, Huzarski T, Pignata S, Colombo N, Park-Simon TW, Tamura K, Sonke GS, Freimund AE, Lee CK, Pujade-Lauraine E. Frenel JS, et al. Among authors: aryal n. Ann Oncol. 2022 Oct;33(10):1021-1028. doi: 10.1016/j.annonc.2022.06.011. Epub 2022 Jun 27. Ann Oncol. 2022. PMID: 35772665 Free article. Clinical Trial.
Corrigendum to "Retinopathy risk calculators in the prediction of sight-threatening diabetic retinopathy in type 2 diabetes: A FIELD substudy" [Diab. Res. Clin. Pract. 186 (2022) 109835].
Rao BN, Quinn N, Januszewski AS, Peto T, Brazionis L, Aryal N, O'Connell RL, Li L, Summanen P, Scott R, O'Day J, Keech AC, Jenkins AJ; FIELD Study Group. Rao BN, et al. Among authors: aryal n. Diabetes Res Clin Pract. 2023 Feb;196:110234. doi: 10.1016/j.diabres.2022.110234. Epub 2023 Jan 4. Diabetes Res Clin Pract. 2023. PMID: 36609014 No abstract available.
Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study.
Trillsch F, Mahner S, Ataseven B, Asher R, Aryal N, Dubot C, Clamp A, Penson RT, Oza A, Amit A, Huzarski T, Casado A, Scambia G, Friedlander M, Colombo N, Fujiwara K, Sonke GS, Denys H, Lowe ES, Lee CK, Pujade-Lauraine E. Trillsch F, et al. Among authors: aryal n. Gynecol Oncol. 2022 Apr;165(1):40-48. doi: 10.1016/j.ygyno.2022.01.024. Epub 2022 Jan 31. Gynecol Oncol. 2022. PMID: 35115180 Clinical Trial.
Retinopathy risk calculators in the prediction of sight-threatening diabetic retinopathy in type 2 diabetes: A FIELD substudy.
Rao BN, Quinn N, Januszewski AS, Peto T, Brazionis L, Aryal N, O'Connell RL, Li L, Summanen P, Scott R, O'Day J, Keech AC, Jenkins AJ; FIELD Study Group. Rao BN, et al. Among authors: aryal n. Diabetes Res Clin Pract. 2022 Apr;186:109835. doi: 10.1016/j.diabres.2022.109835. Epub 2022 Mar 18. Diabetes Res Clin Pract. 2022. PMID: 35314259
Uric acid predicts long-term cardiovascular risk in type 2 diabetes but does not mediate the benefits of fenofibrate: The FIELD study.
Cao JY, Waldman B, O'Connell R, Sullivan DR, Scott RS, Aryal N, Gebski V, Marschner I, Taskinen MR, Simes JR, McGill N, Jenkins AJ, Keech AC; FIELD investigators. Cao JY, et al. Among authors: aryal n. Diabetes Obes Metab. 2020 Aug;22(8):1388-1396. doi: 10.1111/dom.14046. Epub 2020 Apr 22. Diabetes Obes Metab. 2020. PMID: 32243036 Clinical Trial.
Advances in Nano-Electrochemical Materials and Devices.
Wang M, Chen X, Aryal N. Wang M, et al. Among authors: aryal n. Nanomaterials (Basel). 2024 Apr 18;14(8):712. doi: 10.3390/nano14080712. Nanomaterials (Basel). 2024. PMID: 38668206 Free PMC article.
101 results